A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Clinical trial NCT05144841 · COMPLETED
Trial details
- NCT number
- NCT05144841
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-08
- Primary completion
- 2026-04-21
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.